Sai Life Sciences (SAILIFE) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 began with strong momentum, driven by robust growth in discovery, development, and commercial manufacturing, underpinned by deep partnerships with global pharma innovators and operational excellence.

• Strategic progress included the launch of new biology and peptide research facilities, expansion of R&D and manufacturing capacity, and onboarding of over 250 scientists and technical professionals.

• Focused on scaling execution, strengthening client partnerships, and investing in technology and talent for sustained long-term value.

• Board approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2025.

• Eleven client and regulatory audits were successfully completed, reinforcing a strong compliance record.

Financial highlights

• Q1 FY26 consolidated revenue reached INR 4,964.19 million (₹496 Cr), up 77% year-over-year from INR 2,797.23 million (₹218 Cr) in Q1 FY25.

• CDMO business revenue grew 113% year-over-year to INR 3,140 million (₹314 Cr); CRO/Discovery revenue rose 38% to INR 1,820 million (₹182 Cr).

• EBITDA increased 305% year-over-year to INR 1,250 million (₹125 Cr), with margins expanding to 25%, a 14% improvement.

• PAT turned positive at INR 604.55 million (₹60 Cr), compared to a loss of INR 134.98 million in Q1 FY25.

• Capital expenditure for the quarter was INR 1,340 million (₹134 Cr), with a full-year CapEx plan of INR 7,000 million (₹700 Cr).

Outlook and guidance

• Management expects the historical trend of stronger H2 performance to continue, with a targeted 15-20% revenue CAGR over 3-5 years and 28-30% EBITDA margins over the next 2-3 years.

• Strategic investments are set to double process R&D capacity by next year and increase manufacturing capacity by 80% by FY27.

• Capacity utilization for Q1 was around 77%, with plans to bridge interim capacity gaps before new blocks come online in FY27.

• No explicit forward-looking guidance provided in statutory filings, but continued focus on core CRDMO segment and prudent capital allocation indicated.